Tag: boston-scientific
-
Boston Scientific (BSX): Growth, Cash Flow, and Reimbursement Risk — Analysis
Boston Scientific (BSX) is rated Buy as double-digit growth and improving free cash flow support a premium valuation. Q1 2026 revenue rose 11.6% and EBITDA jumped 32.3%, but reimbursement and pricing pressure remain key risks.